| Title: |
High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience |
| Authors: |
Lewis F. Nasr; Marianne Zoghbi; Rossana Lazcano; Michael Nakazawa; Andrew J. Bishop; Ahsan Farooqi; Devarati Mitra; Beverly Ashleigh Guadagnolo; Robert Benjamin; Shreyaskumar Patel; Vinod Ravi; Dejka M. Araujo; Andrew Livingston; Maria A. Zarzour; Anthony P. Conley; Ravin Ratan; Neeta Somaiah; Alexander J. Lazar; Christina Roland; Emily Z. Keung; Elise F. Nassif Haddad |
| Source: |
Cancers, Vol 16, Iss 9, p 1763 (2024) |
| Publisher Information: |
MDPI AG |
| Publication Year: |
2024 |
| Collection: |
Directory of Open Access Journals: DOAJ Articles |
| Subject Terms: |
immunotherapy; anti-PD1; real world; sarcoma; undifferentiated pleomorphic sarcomas; survival; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282 |
| Description: |
Background: Undifferentiated pleomorphic sarcomas (UPSs) are amongst the most common subtypes of soft-tissue sarcomas. Few real-world data on the use of immune checkpoint blockade (ICB) in UPS patients and other high-grade pleomorphic STS patients are available. Purpose: The purpose of our study is to describe the efficacy and toxicity of ICB in patients with advanced UPSs and other high-grade pleomorphic sarcomas treated at our institution. Methods: This is a retrospective, observational study of all patients with metastatic high-grade pleomorphic sarcomas treated with FDA-approved ICB at MD Anderson Cancer Center between 1 January 2015 and 1 January 2023. Patients included in trials for which results are not yet published were excluded. Results: Thirty-six patients with advanced/metastatic pleomorphic sarcomas were included. The median age was 52 years. A total of 26 patients (72%) had UPSs and 10 patients (28%) had other high-grade pleomorphic sarcomas. The median follow-up time was 8.8 months. The median PFS was 2.9 months. The 3-month PFS and 6-month PFS were 46% and 32%, respectively. The median OS was 12.9 months. The 12-month OS and 24-month OS were 53% and 29%, respectively. The best response, previous RT, and type of ICB treatment were significantly and independently associated with shorter PFS ( p = 0.0012, p = 0.0019 and p = 0.036, respectively). No new safety signal was identified, and the toxicity was overall manageable with no toxic deaths and only four patients (11%) stopping treatment due to toxicity. Conclusions: Real-world retrospective data are consistent with the published literature, with a promising 6-month PFS of 32%. Partial or stable responders to ICB treatment have significantly improved PFS compared to progressors. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
https://www.mdpi.com/2072-6694/16/9/1763; https://doaj.org/toc/2072-6694; https://doaj.org/article/0a0f97d97b6f4eab81d45c599ea4e336 |
| DOI: |
10.3390/cancers16091763 |
| Availability: |
https://doi.org/10.3390/cancers16091763; https://doaj.org/article/0a0f97d97b6f4eab81d45c599ea4e336 |
| Accession Number: |
edsbas.F4D686DD |
| Database: |
BASE |